cln-081
cullinan oncology,otsuka
['cln-081 ']
cln-081 selective egfr exon 20 tki at 100mg bid dose orr 41%, mpfs 12mo, no grade 3 diarrhea or rash reported, 5% dose discontinuation. preliminary brain efficacy reported #asco22 
MD, PhD - Asst Prof, Thoracic Oncology & Precision Medicine Unit Coordinator (CEMIC). Co-Founder PxMedica: https://t.co/6HpAi0RR9P